Theridian Technologies — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Theridian Technologies is a private, services-oriented firm founded in 2018, operating in the digital health and medical devices sectors as a consultant rather than a product developer. Its business model is built on providing specialized consulting services, including CMC, regulatory support, and business development, to biopharma clients worldwide. The company is revenue-generating, with a client base built through referrals, and is led by President Michael M. Crowley, Ph.D. As a consultancy, it faces no traditional therapeutic pipeline but navigates risks related to client concentration and competition in the crowded life sciences consulting market.

Digital HealthMedical Devices

Technology Platform

Integrated consulting expertise in CMC, regulatory affairs, quality, business development, and DEA compliance for the biopharmaceutical industry.

Opportunities

Growing biopharma outsourcing trends and increasing regulatory complexity, especially in niche areas like controlled substance (DEA) compliance and advanced therapy CMC, create sustained demand.

The global reach of biotech allows for client diversification beyond the U.S.

market.

Risk Factors

Revenue is vulnerable to cyclical downturns in biotech funding and R&D spending.

High competition in life sciences consulting and dependence on a small team for reputation and expertise pose significant business risks.

Competitive Landscape

Competes with a wide range of players from large global CROs and consulting firms to small boutique specialists. Differentiation relies on integrated technical/business expertise, niche regulatory knowledge (e.g., DEA), and personalized service as a smaller firm.

More companies in Digital Health & Biotech SaaS →More companies in United States →